Evidence map›Paper›PMID 41460707›Full record

ArticleJournal of immunotoxicology2026

Modification of the dextran sodium sulfate model to identify agents that induce or exacerbate inflammatory bowel disease.

Victor J Johnson, Michael I Luster, Michael Kashon, Erin M Quist, Gary R Burleson, Florence G Burleson, Dori R Germolec

Abstract read
In one paragraph

Article in Journal of immunotoxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victor J JohnsonBurleson Research Technologies, Inc, Morrisville, NC, USA.
Michael I LusterBurleson Research Technologies, Inc, Morrisville, NC, USA.
Michael KashonMountainview Research Analytics, LLC, Morgantown, WV, USA.
Erin M QuistExperimental Pathology Laboratories, Inc, Durham, NC, USA.
Gary R BurlesonBurleson Research Technologies, Inc, Morrisville, NC, USA.
Florence G BurlesonBurleson Research Technologies, Inc, Morrisville, NC, USA.
Dori R GermolecDivision of Translational Toxicology, National Institute of Environmental Health Sciences, NIH, DHHS, Durham, NC, USA.

Funding

NICHD NIH HHS HHSN273201400017C
6 · The paper itself

Abstract

Exposure to environmental agents has been linked to inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD) in humans. In these studies, we describe a modification of an experimental model used historically in the pharmaceutical industry to help identify therapies for the treatment of IBD to facilitate its use for identification of environmental agents that have the potential to accelerate, exacerbate, and/or impair recovery from IBD. In this model, female C57BL/6 mice were exposed to low levels of dextran sodium sulfate (DSS) for 7 consecutive days in drinking water to allow for a modest level of colon inflammation and pathology as measured by a battery of clinical, pathological, toxicological endpoints (water consumption, body weights, colon length, body temperature, stool consistency, and hematochezia), and cytokine/chemokine production in the serum and colon. Treatment with DSS for 7 d showed a clear dose-response with 1% DSS producing minimal changes in the colon and 3% DSS inducing severe damage with IBD. A concentration of 2% DSS in drinking water for 7 d was selected for investigating disease recovery and exacerbation by an environmental agent as it induced mild colon inflammation that showed nearly complete resolution within 21 d following cessation of DSS exposure. Cytokine and chemokine profiles showed a Type 1 predominant immune response in the colon and serum that is consistent with inflammation observed in human IBD. The model was used to determine the impact of administration of a high salt diet (HSD) on DSS IBD progression, severity, and recovery. While administration of HSD by itself had no effect on indicators of colon damage or inflammation, co-administration of HSD with DSS, produced marked exacerbation and persistence of disease supporting the potential of the model for identifying environmental agents that can affect IBD.

Indexed as

ColonDextran SulfateDisease Models, AnimalInflammatory Bowel DiseasesAnimalsCytokinesFemaleHumansMiceMice, Inbred C57BLCytokinesDextran SulfateCrohn’sIBD exacerbationimmunotoxicityinflammatory bowel diseaseIrritable bowel diseaseulcerative colitis

Identifiers

PMID41460707
PMCPMC12882113

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.